The Wall Street Journal’s headline: “Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date.” The New York Times’ headline: “A large study finds that ivermectin does not reduce risk of Covid-19 hospitalization.” Surely this is cased closed on ivermectin’s ability to help with COVID, right?
Not quite. Once again, the media fail to critically analyze the actual results of a study and instead jump right to the sensationalist headlines that “stick it” to those who dare to question their orthodoxy.
The study suffered from some of the same problems as other studies finding ivermectin to be ineffective. The dosage was too low, treatment was only for three days when it should continue for five days after symptoms subside, and the study population had to have at least one risk factor for severe disease, like a comorbidity or be 50 years or over, which is not representative of the wider population. Further, ivermectin treatment in the study started within seven days of first symptoms, but this is not early enough; ivermectin needs to be started immediately, ideally on day one of symptoms presenting.
Even with the study designed to fail, those in the ivermectin group fared better than the placebo group, though the results were not statistically significant.
What explains the fervent desire among journalists at major institutions and some in the scientific community to show that ivermectin is a failure? Could it be that their sponsors in the drug industry don’t want an off-patent, cheaply available drug to serve as a viable alternative to vaccines or other expensive treatments for COVID like remdesivir? If ivermectin were widely hailed as a success for COVID, attention might start to turn to other off-patent treatments for other diseases, threatening Big Pharma’s ability to re-package their drugs to create new blockbusters that bankrupt our country but make them billions.
Action Alert! Write to the FDA and Congress, telling them to set the record straight on ivermectin! Please send your message immediately.